Fundrasing

CapMan Life Science IV fund closes at EUR 54 million

CapMan Life Science IV fund held its final closing today at EUR 54 million. This makes the fund the largest life science fund managed by CapMan so far.

The fund invests in medical technology and service companies predominantly in the Nordic region.

A total of eight institutional investors joined CapMan Life Science IV, where two represented new investors in CapMan funds. CapMan Plc’s own commitment to the fund is EUR 10 million.  

The fund has already made investments in three companies. Neoventa Medical AB is specialised in fetal monitoring in perinatal healthcare, ProstaLund AB manufactures devices for treatment of benign prostatic hyperplasia and QuickCool AB develops a new method for quick cooling of the brain to prevent brain damage.

Read more

 


Date of Transaction2007-05-24
Closing Final
FundCapMan Life Science IV
ManagerCapMan Capital Management
StageVenture
LocationNorway, Denmark, Sweden, Finland
Ind. FocusLife Science
Fund SizeEUR 54.1m
Vintage Year2006
 

More fundraisings

 
 
Location
Stage
Industry
 
 

Latest PE Voice

Harald Mix on Nordic private equity

- 1/10/2012 10:10:00 AM
At the Argentum Conference in 2010, we asked Harald Mix, Managing Partner and Co-founder of Altor Equity Partners about the outlook for future returns in Nordic private equity.
 
 

Calendar

2012-02-07 in Stockholm

Limited Partners Brief 2012

2012-02-07 in London

LP-GP Forum Clean Energy & Sustainability

2012-02-16 in Bergen

Vestlandskonferansen

2012-02-27 in Berlin

SuperReturn International 2012

2012-03-05 in Copenhagen

Nordic Fundraising Summit
 
Copyright Argentum 2009